Adagio Therapeutics is a US-based company that creates antibody-based solutions for infectious diseases and is currently working on a Phase 3 clinical trial product called ADG20 that targets the coronavirus disease. The company collaborates with Adimab, LLC and the Scripps Research Institute to create proprietary antibodies and identify vaccine candidates respectively. Adagio Therapeutics was founded in 2020 and is headquartered in Waltham, Massachusetts.